Literature DB >> 14630515

Electrostatic potential on human leukocyte antigen: implications for putative mechanism of chronic beryllium disease.

James A Snyder1, Ainsley Weston, Sally S Tinkle, Eugene Demchuk.   

Abstract

The pathobiology of chronic beryllium disease (CBD) involves the major histocompatibility complex class II human leukocyte antigen (HLA). Although occupational exposure to beryllium is the cause of CBD, molecular epidemiologic studies suggest that specific (Italic)HLA-DPB1(/Italic) alleles may be genetic susceptibility factors. We have studied three-dimensional structural models of HLA-DP proteins encoded by these genes. The extracellular domains of HLA-DPA1*0103/B1*1701, *1901, *0201, and *0401, and HLA-DPA1*0201/B1*1701, *1901, *0201, and *0401 were modeled from the X-ray coordinates of an HLA-DR template. Using these models, the electrostatic potential at the molecular surface of each HLA-DP was calculated and compared. These comparisons identify specific characteristics in the vicinity of the antigen-binding pocket that distinguish the different HLA-DP allotypes. Differences in electrostatics originate from the shape, specific disposition, and variation in the negatively charged groups around the pocket. The more negative the pocket potential, the greater the odds of developing CBD estimated from reported epidemiologic studies. Adverse impact is caused by charged substitutions in positions 55, 56, 69, 84, and 85, namely, the exact same loci identified as genetic markers of CBD susceptibility as well as cobalt-lung hard metal disease. These findings suggest that certain substitutions may promote an involuntary cation-binding site within a putatively metal-free peptide-binding pocket and therefore change the innate specificity of antigen recognition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630515      PMCID: PMC1241746          DOI: 10.1289/ehp.6327

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  24 in total

1.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

2.  Beryllium contamination inside vehicles of machine shop workers.

Authors:  W T Sanderson; P K Henneberger; J Martyny; K Ellis; M M Mroz; L S Newman
Journal:  Appl Occup Environ Hyg       Date:  1999-04

3.  HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease.

Authors:  G Lombardi; C Germain; J Uren; M T Fiorillo; R M du Bois; W Jones-Williams; C Saltini; R Sorrentino; R Lechler
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

4.  Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.

Authors:  A P Fontenot; M Torres; W H Marshall; L S Newman; B L Kotzin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

5.  Beryllium health effects in the era of the beryllium lymphocyte proliferation test.

Authors:  L A Maier
Journal:  Appl Occup Environ Hyg       Date:  2001-05

6.  HLA-DP molecules bind cobalt: a possible explanation for the genetic association with hard metal disease.

Authors:  I Potolicchio; A Festucci; P Hausler; R Sorrentino
Journal:  Eur J Immunol       Date:  1999-07       Impact factor: 5.532

Review 7.  Immunomodulation by metals.

Authors:  David A Lawrence; Michael J McCabe
Journal:  Int Immunopharmacol       Date:  2002-02       Impact factor: 4.932

8.  Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69.

Authors:  M Amicosante; N Sanarico; F Berretta; J Arroyo; G Lombardi; R Lechler; V Colizzi; C Saltini
Journal:  Hum Immunol       Date:  2001-07       Impact factor: 2.850

9.  Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity.

Authors:  Milton D Rossman; Jose Stubbs; Chung Wha Lee; Elias Argyris; Eleni Magira; Dimitri Monos
Journal:  Am J Respir Crit Care Med       Date:  2002-03-15       Impact factor: 21.405

10.  HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.

Authors:  L Richeldi; R Sorrentino; C Saltini
Journal:  Science       Date:  1993-10-08       Impact factor: 47.728

View more
  11 in total

Review 1.  Chronic beryllium disease: an updated model interaction between innate and acquired immunity.

Authors:  Richard T Sawyer; Lisa A Maier
Journal:  Biometals       Date:  2010-10-28       Impact factor: 2.949

Review 2.  The role of lymphocyte proliferation tests in assessing occupational sensitization and disease.

Authors:  Stella E Hines; Karin Pacheco; Lisa A Maier
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-04

3.  Crystal structure of HLA-DP2 and implications for chronic beryllium disease.

Authors:  Shaodong Dai; Guinevere A Murphy; Frances Crawford; Douglas G Mack; Michael T Falta; Philippa Marrack; John W Kappler; Andrew P Fontenot
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-31       Impact factor: 11.205

4.  Research to Practice Implications of High-Risk Genotypes for Beryllium Sensitization and Disease.

Authors:  Kathleen Kreiss; Ethan D Fechter-Leggett; Erin C McCanlies; Christine R Schuler; Ainsley Weston
Journal:  J Occup Environ Med       Date:  2016-09       Impact factor: 2.162

5.  Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove.

Authors:  Lori J Silveira; Erin C McCanlies; Tasha E Fingerlin; Michael V Van Dyke; Margaret M Mroz; Matthew Strand; Andrew P Fontenot; Natalie Bowerman; Dana M Dabelea; Christine R Schuler; Ainsley Weston; Lisa A Maier
Journal:  J Immunol       Date:  2012-09-12       Impact factor: 5.422

Review 6.  Gene-environment interaction from international cohorts: impact on development and evolution of occupational and environmental lung and airway disease.

Authors:  Adam Gaffney; David C Christiani
Journal:  Semin Respir Crit Care Med       Date:  2015-05-29       Impact factor: 3.119

7.  Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry.

Authors:  Michael V Van Dyke; John W Martyny; Margaret M Mroz; Lori J Silveira; Matt Strand; Donna L Cragle; William G Tankersley; Susan M Wells; Lee S Newman; Lisa A Maier
Journal:  Occup Environ Med       Date:  2011-04-02       Impact factor: 4.402

8.  Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers.

Authors:  Mike V Van Dyke; John W Martyny; Margaret M Mroz; Lori J Silveira; Matt Strand; Tasha E Fingerlin; Hiroe Sato; Lee S Newman; Lisa A Maier
Journal:  Am J Respir Crit Care Med       Date:  2011-03-11       Impact factor: 21.405

Review 9.  Beryllium exposure: dermal and immunological considerations.

Authors:  Gregory A Day; Aleksandr B Stefaniak; Ainsley Weston; Sally S Tinkle
Journal:  Int Arch Occup Environ Health       Date:  2005-10-18       Impact factor: 3.015

10.  Impact of negatively charged patches on the surface of MHC class II antigen-presenting proteins on risk of chronic beryllium disease.

Authors:  James A Snyder; Eugene Demchuk; Erin C McCanlies; Christine R Schuler; Kathleen Kreiss; Michael E Andrew; Bonnie L Frye; James S Ensey; Marcia L Stanton; Ainsley Weston
Journal:  J R Soc Interface       Date:  2008-07-06       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.